SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target

Br J Haematol. 2019 Apr;185(1):145-147. doi: 10.1111/bjh.15393. Epub 2018 May 22.

Authors

John Shi¹, Juraj Bodo¹, Xiaoxian Zhao¹, Lisa Durkin¹, Tanu Goyal^{1

2}, Howard Meyerson², Eric D Hsi¹

Affiliations

¹ Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
² Department of Pathology, University Hospitals, Cleveland, OH, USA.

PMID: 29785767
DOI: 10.1111/bjh.15393

No abstract available

Keywords: antibody therapy; diagnostic haematology; lymphomas.

Publication types

Letter

MeSH terms

Biomarkers
Biomarkers, Tumor*
Humans
Immunohistochemistry
Immunophenotyping
Molecular Targeted Therapy
Phenotype
Plasmablastic Lymphoma / diagnosis*
Plasmablastic Lymphoma / drug therapy
Plasmablastic Lymphoma / genetics*
Plasmablastic Lymphoma / metabolism
Prognosis
Signaling Lymphocytic Activation Molecule Family / genetics*
Signaling Lymphocytic Activation Molecule Family / metabolism

Substances

Biomarkers
Biomarkers, Tumor
SLAMF7 protein, human
Signaling Lymphocytic Activation Molecule Family